FDA
-
-
-
-
-
-
-
BioMarin Reports First Quarter 2026 Financial and Operating Results
-
-
-
-
-
-
-
BioMarin reports early VOXZOGO treatment benefits for achondroplasia
-
-
-
-
-
-
-
BioMarin (BMRN), Ascendis (ASND) Trade Lower Following Competitor Data
-
-
-
-
-
-
-
BioMarin Shares New Data Reinforcing Its Leadership in Bone Health at the American Society for Bone and Mineral Research Annual Meeting
-
-
-
-
-
-
-
BioMarin Pharma (BMRN) Presents Five-Year Phase 3 Results Reinforcing Long-Term Efficacy and Safety of ROCTAVIAN at International Society on Thrombosis and Haemostasis 2025 Congress
-
-
-
-
-
-
-
BioMarin Pharma (BMRN) Announces Positive Pivotal Data for PALYNZIQ in Adolescents with Phenylketonuria
-
-
-
-
-
-
-
BioMarin Announces 28% Y/Y Total Revenue Growth in the Third Quarter and Increase in Full-year 2024 Guidance; Reaffirms Long-term Guidance and Outlook
-
323,900 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

